Stock IRON DISC MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Disc Medicine, Inc.

Equities

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
33.17 USD +6.11% Intraday chart for Disc Medicine, Inc. +4.11% -42.57%
May. 09 Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating MT

Business Summary

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Number of employees: 78

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,721,465 20,236,682 ( 81.86 %) 0 81.86 %

Shareholders

NameEquities%Valuation
Access Industries, Inc. (New York)
12.73 %
3,141,759 12.73 % 83 M $
Paradigm BioCapital Advisors LP
9.683 %
2,389,902 9.683 % 63 M $
Atlas Venture Life Science Advisors LLC
9.267 %
2,287,233 9.267 % 61 M $
OrbiMed Advisors Private Equity
6.897 %
1,702,237 6.897 % 45 M $
Bain Capital Life Sciences LP
5.337 %
1,317,213 5.337 % 35 M $
STATE STREET CORPORATION
4.421 %
1,091,211 4.421 % 29 M $
T. Rowe Price International Ltd.
3.826 %
944,213 3.826 % 25 M $
Perceptive Advisors LLC
3.808 %
939,866 3.808 % 25 M $
BlackRock Advisors LLC
3.428 %
846,091 3.428 % 22 M $
Frazier Life Sciences Management LP
3.181 %
785,000 3.181 % 21 M $

Company contact information

Disc Medicine, Inc.

321 Arsenal Street Suite 101

02472, Watertown

+

http://www.discmedicine.com
address Disc Medicine, Inc.(IRON)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
33.17 USD
Average target price
57.33 USD
Spread / Average Target
+72.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DISC MEDICINE, INC. Stock Disc Medicine, Inc.
-42.57% 820M
MODERNA, INC. Stock Moderna, Inc.
+64.23% 62.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.31% 41.18B
LONZA GROUP AG Stock Lonza Group AG
+45.38% 40.29B
CELLTRION, INC. Stock Celltrion, Inc.
-8.29% 27.9B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.97% 26.21B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.16% 19.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.54% 13.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.17% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.72% 12.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IRON Stock
  4. Company Disc Medicine, Inc.